• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively unimpaired older adults

byJack LennonandAlex Chan
July 6, 2021
in Chronic Disease, Neurology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In the context of elevated amyloid-beta, IL-12p70 was associated with slower cognitive decline.

2. IFN-γ was associated with slower cognitive decline irrespective of amyloid-beta deposition.

Evidence Rating Level: 2 (Good)

It is currently understood that immune dysregulation, as well as premature immunosenescence and cytokine levels, impact the neurodegenerative process. Less understood, however, is the predictive value of cytokine levels in the context of cognitive trajectories in cognitively unimpaired individuals. This is particularly important among those who are amyloid-beta- (Aβ) positive. This longitudinal study assessed baseline plasma for nine cytokines of 298 cognitively unimpaired older adults (50 to 90 years old) to determine whether or not these biomarkers were associated with cognitive decline and Aβ deposition. Cytokine levels were also compared to Aβ and tau PET as well as neurodegeneration. Eligible participants had a score of 27 or greater on the age- and education-adjusted Mini Mental Status Examination and scored with the normatively average range on several other neuropsychological measures. Those with unstable medical or psychiatric conditions, as well as those with a stroke history, were excluded. Elevated IL-12p70 was found to be associated with slower cognitive decline in the context of increased Aβ (false discovery rate [FDR] = 0.0023). Conversely, IFN-γ was associated with cognitive decline irrespective of Aβ findings (FDR = 0.013). Elevated IL-12p70 was also associated with reduced neurodegeneration and tau protein in those with elevated Aβ. Overall, this study demonstrates the role of immune dysregulation in neurodegeneration, such that certain cytokines may serve a protective role in slowing cognitive decline in those with and without elevated Aβ.

Click to read the study in Alzheimer’s and Dementia

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

Tags: dementia
Previous Post

Sleep and pain may share a bi-direction relationship amongst patients with chronic musculocutaneous pain

Next Post

Improved sleep quality reduced cardio-metabolic risk factors

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 21, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Chronic Disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

May 31, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

May 19, 2022
Next Post

Improved sleep quality reduced cardio-metabolic risk factors

Intrauterine Zika virus infection associated with significant fetal brain abnormalities

Wolbachia-infected mosquitos decreased the incidence of symptomatic dengue fever

Mental health parity law associated with financial protection for children

Survey finds high rates of childhood abuse among transgender adolescents

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.